Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dane...i had seen the site but only was alerted through Napodano's tweet...went to yahoo message board and saw the posts there and followed to that site...i think that gofundme site is raising money for a specific cause for jesi...still a rumor as i said and nothing has been confirmed by a third party...the person running the site does seem to have jesi's interest in mind...i hope its true for jesi's sake...hog
no i know...that it is an NVIV investor site...that is why i said caution...hog
NVIV...from twitter...
Jason Napodano, CFA ?@JNapodano 2m2 minutes ago
IF that's true, $NVIV would be 2-for-2 in terms of patients regaining function after being classified AIS-A complete.
0 retweets 1 favorite
Reply Retweet Favorite1
More
Jason Napodano, CFA ?@JNapodano 4m4 minutes ago
$NVIV shares soaring now on -unconfirmed- news that Jesi (pt #2) has regained some movement in her hips. source: GoFundMe page
NVIV... http://www.gofundme.com/Jesi-NVIVGivesBack this is where the rally is coming from...hog
i think the trip back to the hospital had to do with a medication that she didnt accept very well..that happens...here is where the info is on jesi..hog
http://www.gofundme.com/Jesi-NVIVGivesBack
NVIV...moving large on rumors of 2nd pt moving legs...hog
$NVIV...HOD..hog
NVIV moving...hog
$NVIV moving...hog
$IPCI...its going to be freaking nutso..we are doing this on 50k volume
.hog
NVIV...just a caution...yahoo message board...someone posted jesi has moved her leg on her own..hog
Wow, Jesi is moving her legs on her own.
by alleg180 • 25 minutes ago Flag
Video to come...
.Napodano on twitter is posting...
Jason Napodano, CFA ?@JNapodano 10m10 minutes ago
I would not believe any news on Jesi or Jordan unless you hear it directly from them or $NVIV. Trying to confirm some things right now.
NVIV...just a caution...yahoo message board...someone posted jesi has moved her leg on her own..
Wow, Jesi is moving her legs on her own.
by alleg180 • 25 minutes ago Flag
Video to come...
.Napodano on twitter is posting...
Jason Napodano, CFA ?@JNapodano 10m10 minutes ago
I would not believe any news on Jesi or Jordan unless you hear it directly from them or $NVIV. Trying to confirm some things right now.
just a caution...hog
$ATHX..."Athersys Inc.'s MultiStem could very well be among the first few products approved in Japan."
http://www.thelifesciencesreport.com/pub/na/will-stem-cell-profits-measure-up-nxr-biotechnologies-alain-vert-s
$MEIP...i dont know anything about this blogger...just throwing it out there...hog
Upcoming catalyst for MEI Pharma (odds: 90%)
2015-03-18yixiLeave a comment
MEI Pharma (NASDAQ:MEIP) will report topline data from the Phase II trial (MEI-003) of pracinostat plus azacitidine in first-line myelodysplastic syndrome (MDS) in March 2015. I strongly believe the results will be positive.
Pracinostat (SB939) is a HDAC inhibitor discoved by S*Bio. MEI Pharma acquired the compound for $75.7 million in Augest 2012. The FDA has approved three HDAC inhibitors, known as Zolinza (vorinostat), Istodax (romidepsin) and Beleodaq (belinostat), for the treatment of PTCL. MEI Pharma is testing pracinostat in three Phase II trails: (1) first-line MDS (MEI-003); (2) AML (MEI-004); (3) 2nd-line MDS (MEI-005).
In the earlier pilot Phase II trial, pracinostat plus azacitidine showed an ORR of 89% (8/9) including 78% patients who achieved CR/CRi. Historical ORR for Vidaza (azacitidine) in MDS is only 16%[1]. These data led to a new Phase II trial (MEI-003) evaluating pracinostat plus azacitidine vs. placebo plus azacitidine with a primary endpoint of CR.
I believe pracinostat plus azacitidine will demonstrate a huge improvement over azacitidine alone. Forthermore, interim analysis from the MEI-005 trial revealed an ORR of 3/28 in patients who have previously failed azacitidine or decitabine alone. This data in refractory MDS further proves pracinostat’s impressive clinical efficacy.
Approximately 13,000 patients in the U.S. are diagnosed with MDS each year. Cowen and Company analyst Nicholas Bishop expects pracinostat to generate sales of $500 million or more in MDS. According to TipRanks, the average price target for MEIP is $12.83.
[1] Oncologist. 2005, 10(3), 176-182.
https://yixiblog.wordpress.com/2015/03/18/upcoming-catalyst-for-mei-pharma-odds-90/
$IMNP 2015 loaded with catalysts http://docdroid.net/v0xl
$IMNP...my gf doing well with this one...hog
Moves like that make you want to call the hawgs...
$NSPR...yep created when secondary announced...chart looks beautiful...hog
$NSPR up over 5% on increasing volume...link back for nice looking chart...hog
$ADMP...Following the whale...Michael Castor of SIO...hog
$CYNAF...Cynapsus Readies For Pivotal Program With Transformative Parkinson's Drug
http://bionapcfa.blogspot.com/2015/03/cynapsus-readies-for-pivotal-program.html
from twitter...Jason Napodano, CFA @JNapodano · 4h 4 hours ago
I'm dialed into the $CYNAF / $CTH.TO analyst & investor presentation. Will have an update out shortly after.
Jason Napodano, CFA @JNapodano · 4h 4 hours ago
I'm dialed into the $CYNAF / $CTH.TO analyst & investor presentation. Will have an update out shortly after.
$NSPR..added today Mark...
this info is 3 months old but i like what they are doing...also recent second was priced at .40...hog
Alan Milinazzo, CEO of InspireMD, commented, “We are very pleased to have received the CE mark approval for our CGuard RX rapid exchange system. This is an important milestone for the Company as it creates significant near term commercial opportunities for us.” He stated, “Physicians continue to be impressed with the superior clinical data and our 6 month results further validate that CGuard with MicroNet may represent a superior next generation of stenting technology. We plan to use the new clinical data and the RX approval to expand our commercial launch activities starting immediately.”
http://www.inspiremd.com/en/press-center/inspiremd-receives-ce-mark-approval-new-cguard-rx-announces-positive-six-month-follow-carenet-trial-data-linc-2015/
$TROV...sold 3/4 of my holding at $7.88 from $5.03 purchase
$TGTX...sold 3/4 of my holding at $18.68 from $12.60
$NSPR purchased small amt at .31...hog
agreed...been looking for a place to add...hog
$BIAD...added yesterday...will have a bid price today...hog
lol...its been ugly...hog
$CPXX...from twitter... US Banking News ?@AmericanBanking 59m59 minutes ago
Celator Pharmaceuticals $CPXX Posts Earnings Results, Beats Estimates By $0.09 EPS http://ift.tt/18GXhUA